Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04605159
Recruitment Status : Recruiting
First Posted : October 27, 2020
Last Update Posted : January 19, 2021
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The purpose of this study is to evaluate the ability of a single dose of the investigational RSV Maternal vaccine, administered intramuscularly to pregnant women aged 18-49 years, in good general maternal health, in preventing medically assessed RSV associated Lower Respiratory Tract Illnesses (LRTIs) in infants born to vaccinated mothers. The study will also evaluate the safety of the investigational RSV Maternal vaccine both in vaccinated mothers and in their corresponding infant.

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus Infections Biological: RSV MAT Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Actual Study Start Date : November 20, 2020
Estimated Primary Completion Date : August 1, 2023
Estimated Study Completion Date : February 2, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RSV_MAT Group
Maternal participants randomized to the RSV_MAT Group will receive a single dose of RSV MAT vaccine at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm
Biological: RSV MAT
One dose of RSV MAT vaccine reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.

Placebo Comparator: Control Group
Maternal participants randomized to the Control Group will receive a single dose of Placebo at day 1, via the intramuscular route; the preferred injection site will be the deltoid region of the non-dominant arm
Drug: Placebo
One dose of lyophilized sucrose reconstituted with NaCl solution administered intramuscularly in the non-dominant arm.




Primary Outcome Measures :
  1. Number of infant participants with medically assessed, RSV-associated LRTIs, up to 6 months of age [ Time Frame: From birth to Day 181 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of severe (including very severe) and/or any medically assessed, RSV-associated LRTIs.


Secondary Outcome Measures :
  1. Number of infant participants with RSV-associated hospitalizations [ Time Frame: From birth to Day 181 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of RSV associated hospitalizations.

  2. Number of infant participants with all-cause LRTIs [ Time Frame: From birth to Day 181 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of all-cause LRTIs.

  3. Number of infant participants with all-cause LRTIs with hospitalization [ Time Frame: From birth to Day 181 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of all-cause LRTIs with hospitalization.

  4. Number of infant participants with medically assessed, RSV-associated severe (including very severe) LRTIs, up to 7 months of age [ Time Frame: From birth to Day 211 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of medically assessed, RSV-associated severe (including very severe) LRTIs.

  5. Number of infant participants with medically assessed, RSV-associated severe (including very severe) LRTIs, up to 8 months of age [ Time Frame: From birth to Day 241 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of medically assessed, RSV-associated severe (including very severe) LRTIs.

  6. Number of infant participants with medically assessed, RSV-associated severe (including very severe) LRTIs, up to 9 months of age [ Time Frame: From birth to Day 271 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of medically assessed, RSV-associated severe (including very severe) LRTIs.

  7. Number of infant participants with any medically assessed, RSV-associated LRTIs, up to 7 months of age [ Time Frame: From birth to Day 211 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of any medically assessed, RSV-associated LRTIs.

  8. Number of infant participants with any medically assessed, RSV-associated LRTIs, up to 8 months of age [ Time Frame: From birth to Day 241 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of any medically assessed, RSV-associated LRTIs.

  9. Number of infant participants with any medically assessed, RSV-associated LRTIs, up to 9 months of age [ Time Frame: From birth to Day 271 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of any medically assessed, RSV-associated LRTIs.

  10. Number of infant participants with medically assessed, RSV-associated LRTIs, up to 4 months of age [ Time Frame: From birth to Day 121 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of severe (including very severe) and any medically assessed, RSV-associated LRTIs.

  11. Number of infant participants with medically assessed, RSV LRTIs [ Time Frame: From birth to Day 181 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of medically assessed, RSV LRTIs.

  12. Number of infant participants with all-cause pneumonia [ Time Frame: From birth to Day 181 post birth ]
    The vaccine arm will be compared to the placebo arm through the occurrence of all-cause pneumonia.

  13. Time to first occurrence of severe (including very severe) and any medically assessed, RSV-associated LRTIs [ Time Frame: From birth to Day 181 post birth ]
    The vaccine arm will be compared to the placebo arm through the time to first occurrence of severe (including very severe) and any medically assessed, RSV-associated LRTIs.

  14. Number of maternal participants with RSV-associated Medically Attended RTIs (RSV-MA-RTIs) [ Time Frame: From Day 1 (vaccination) to Day 181 post delivery ]
    The vaccine arm will be compared to the placebo arm through the occurrence of RSV-associated MA-RTIs

  15. Humoral immune response in terms of RSV MAT immunoglobulin G (IgG) antibody Geometric Mean Concentration (GMCs) in maternal participants, at specified timepoints [ Time Frame: Day 1 (pre vaccination), Day 31 and at delivery ]
    Serological assays for the determination of IgG antibodies against RSV MAT are performed by Enzyme-Linked Immunosorbent Assay (ELISA).

  16. Humoral immune response in terms of RSV neutralizing antibody Geometric Mean Titers (GMTs) in maternal participants, at specified timepoints [ Time Frame: At Day 1 (pre vaccination), Day 31 and at Delivery ]
    Serological assays for the determination of antibodies against RSV-A and B are performed by neutralization assay.

  17. Humoral immune response in terms of RSV MAT IgG antibody GMCs in infant participants, at specified timepoints [ Time Frame: At birth, Day 43 post birth, Day 121 post birth and Day 181 post birth ]
    Serological assays for the determination of IgG antibodies against RSV MAT are performed by ELISA.

  18. Humoral immune response in terms of RSV neutralizing antibody GMTs in infant participants, at specified timepoints. [ Time Frame: At birth, Day 43 post birth, Day 121 post birth and Day 181 post birth ]
    Serological assays for the determination of antibodies against RSV-A and B are performed by neutralization assay.

  19. Geometric mean ratio between cord blood and maternal RSV MAT IgG-specific antibody concentrations [ Time Frame: At delivery or birth ]
    Transfer of RSV-specific antibodies from maternal participants vaccinated with RSV Mat to their infants is calculated as the ratio between cord blood* and maternal RSV MAT IgG-specific antibody concentrations. * or an infant blood sample collected within 72 hours after birth (if no cord blood sample can be obtained)

  20. Number of maternal participants with solicited adverse events (AEs) [ Time Frame: From Day 1 to Day 7 ]
    Assessed solicited administration site events include pain, redness and swelling, at the injection site. Assessed solicited systemic events include fatigue, fever, nausea, vomiting, diarrhoea, abdominal pain and headache.

  21. Number of maternal participants with unsolicited AEs [ Time Frame: From Day 1 to Day 30 ]
    Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is to be reported as an unsolicited AE.

  22. Number of maternal participants with at least one serious adverse event (SAE), AE leading to study termination or medically attended respiratory tract illness (MA-RTI) [ Time Frame: From Day 1 (vaccination) to Month 6 post delivery ]
    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. MA-RTI occurs when the maternal participant visits a healthcare professional (e.g., a General Practitioner) for any respiratory symptom, including (but not limited to) cough, sore throat, sputum production and difficulty breathing.

  23. Number of maternal participants with at least one other medically attended AE [ Time Frame: From Day 1 (vaccination) to Day 43 post delivery ]
    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

  24. Number of maternal participants with each pregnancy outcome [ Time Frame: From Day 1 to Day 43 post delivery ]
    These pregnancy outcomes include live birth with no congenital anomalies, live birth with minor congenital anomaly(ies) only; live birth with at least one major congenital anomaly, fetal death/still birth (antepartum or intrapartum) with no congenital anomalies, fetal death/still birth (antepartum or intrapartum) with only minor congenital anomalies, fetal death/still birth (antepartum or intrapartum) with at least 1 major congenital anomaly; elective/therapeutic termination with no congenital anomalies; elective/therapeutic termination with only minor congenital anomalies, and elective/therapeutic termination with at least 1 major congenital anomaly.

  25. Number of maternal participants with each pregnancy-related AE of special interest (AESI) [ Time Frame: From Day 1 (vaccination) to Day 43 post delivery ]
    These pregnancy-related AESIs include maternal death, hypertensive disorders of pregnancy, fetal growth restriction, pathways to preterm birth, gestational diabetes mellitus and chorioamnionitis.

  26. Number of infant participants with each neonatal AESI [ Time Frame: From birth to Day 43 post birth ]
    Neonatal AESIs include small for gestational age, low birth weight including very low and extremely low birth weight, congenital anomalies, neonatal death, preterm birth.

  27. Number of infant participants with at least one SAE, AE leading to study termination or Medically Attended AEs (MAE), from birth up to 6 months after birth [ Time Frame: From birth to Month 6 post birth ]
    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. A MAE is an unsolicited AE such as a symptom or illness which requires a hospitalisation, or emergency room visit, or visit to/by a health care provider.

  28. Number of infant participants with at least one SAE, AE leading to study termination or MAE, from birth up to 12 months after birth [ Time Frame: From birth to Month 12 post birth ]
    A SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study participant. A MAE is an unsolicited AE such as a symptom or illness which requires a hospitalisation, or emergency room visit, or visit to/by a health care provider.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Maternal participants

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Participants who give written or witnessed/thumb printed informed consent after the study has been explained, and before any study specific procedures are performed, as per local regulations regulatory requirements.
  • Age 18 to 49 years, inclusive, at the time of study intervention.
  • Pre-pregnancy BMI 18.5 to 39.9 kg/m2, inclusive.
  • In good general maternal health as established by medical history and clinical examination before entering into the study.
  • Singleton pregnancy (including instances where the singleton pregnancy derives from a vanishing twin syndrome).
  • At 24^0/7 to 34^0/7 weeks of gestation at the time of study vaccination (Visit 1), as established by:
  • last menstrual period (LMP) date corroborated by first or second trimester ultrasound examination (U/S) i.e. at or before 28 weeks of gestation.
  • 1st or 2nd trimester U/S only, if LMP is unknown/uncertain
  • Certain LMP, corroborated by an U/S performed after 28 weeks of gestation is also acceptable.
  • No fetal genetic abnormalities (based on genetic testing, if performed).
  • No significant congenital malformations, as assessed by fetal anomaly ultrasound scan conducted at or beyond 18 weeks of gestation.
  • Willing to provide cord blood.
  • Who do not plan to give their child for adoption.
  • Who plan to reside in the study area for at least one year after delivery.
  • Willing to have the infant followed-up after delivery for a period of 12 months.

Infant participants

  • Live-born from the study pregnancy.
  • If required per local regulations/guidelines, re-signed (confirmed) written or witnessed/thumb printed informed consent for study participation of the infant obtained from the infant's mother and/or father and/or LAR, before performing any study specific procedure. OR, if permitted by local regulation, documented verbal consent for infant's participation obtained from the parent(s)/LAR(s) at birth, followed by written consent obtained by (or before) Visit 2-newborn.

Exclusion Criteria:

Maternal participants Medical conditions

  • History of allergic disease or reactions likely to be exacerbated by any component of the RSV vaccine
  • Hypersensitivity to latex
  • Significant complications in the current pregnancy:
  • Gestational hypertension unless blood pressure it is controlled and maintained in the normal range (<140mmHg and <90mmHg) through diet and/or antihypertensive medications
  • Gestational diabetes not controlled by medication, diet and/or exercise
  • Pre-eclampsia
  • Eclampsia
  • Intrauterine Growth Restriction/Fetal Growth Restriction
  • Placenta previa
  • Placental abruption, placenta accreta/percreta/increta, chorioamnionitis or any abnormalities that can impair the maternal-fetal circulation
  • Polyhydramnios
  • Oligohydramnios
  • Preterm labour or history of preterm labour in the current pregnancy
  • Any intervention to prevent preterm delivery or medical treatment for suspected preterm delivery, including administration of systemic corticosteroids for fetal lung maturation
  • Cholestasis
  • Other pregnancy-related complications (per investigator's judgement)
  • Significant structural abnormalities of the uterus or cervix
  • History of 2 or more prior stillbirths or neonatal deaths/history of 2 or more preterm births at ≤34 weeks gestation/3 or more consecutive spontaneous abortions
  • Known HIV infection (as per serological tests performed during the current pregnancy)
  • Known or suspected HBV or HCV infection
  • Known or suspected infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Zika, Rubella, Varicella, CMV or primary genital Herpes Simplex
  • Active infection with tuberculosis
  • Known or suspected impairment of the immune system
  • Current autoimmune disorder for which the participant has received immune-modifying therapy within 6 months before study vaccination, or plans administration through delivery
  • Lymphoproliferative disorder or malignancy within 5 years before study vaccination
  • Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions that might pose additional risk to the participant due to participation in the study
  • Any conditions that may interfere with participant's ability to comply with study procedures or receipt of prenatal care
  • Any condition which would increase the risks of study participation to the unborn infant

Prior/Concomitant therapy

  • Prior receipt of an RSV vaccine in the current pregnancy
  • Use of any investigational/non-registered product other than the study vaccine/product as described below, or planned use during the period :
  • For a drug, vaccine or medical device: from 29 days before the dose of study vaccine
  • For immunoglobulins: 3 months before the dose of study vaccine/product.

The exception to this is investigational products administered in the setting of a pandemic which may be allowed following delivery

  • Planned administration/administration of any vaccine from 29 days before the dose of study vaccine or planned administration through delivery, except:
  • Seasonal influenza vaccines, tetanus vaccines, dTpa/Tdap - alone vaccines, dTpa/Tdap vaccines that also contain other antigens and Hepatitis B vaccines, all of which may be administered according to standard of care ≥15 days before or after study vaccination
  • Administration of immunoglobulins (except anti-Rh0D IG, which may be administered at any time), blood products or plasma derivatives within 3 months before study vaccination or planned administration through delivery
  • Administration of immune-modifying therapy within 6 months before the study vaccination, or planned administration through delivery. This includes but is not limited to:
  • Azathioprine, mycophenolate mofetil, 6-mercaptopurine, cyclosporine, tacrolimus, monoclonal or polyclonal antibodies
  • Prednisone ≥5 mg/day or equivalent for ≥14 days; Inhaled, intra-articular/intra-bursal and topical steroids are allowed
  • Corticosteroids administered for fetal lung maturation

Prior/Concurrent clinical study experience

- Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product

Other exclusions

  • Alcoholism or substance use disorder within the past 24 months based on DSM-5 criteria
  • A local condition that precludes injection of the study vaccine/product or precludes assessment of local reactogenicity
  • Consanguinity of maternal participant and her partner (second degree cousins or closer)
  • Any study personnel or their immediate dependants, family or household members

Infant participants

  • Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product
  • Any condition which would increase the risks of study participation to the infant
  • Child in care.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04605159


Contacts
Layout table for location contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 89904466 GSKClinicalSupportHD@gsk.com

Locations
Layout table for location information
United States, Alabama
GSK Investigational Site Recruiting
Birmingham, Alabama, United States, 35205
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Charles E Sharp         
GSK Investigational Site Recruiting
Dothan, Alabama, United States, 36301
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Guy Middleton         
GSK Investigational Site Recruiting
Mobile, Alabama, United States, 36608
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Charles M Rogers IV         
United States, Arizona
GSK Investigational Site Recruiting
Phoenix, Arizona, United States, 85015
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Charles S Plimpton         
United States, California
GSK Investigational Site Recruiting
Los Angeles, California, United States, 90057
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Peyman Banooni         
United States, Idaho
GSK Investigational Site Recruiting
Blackfoot, Idaho, United States, 83221
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Gary Soucie         
GSK Investigational Site Recruiting
Idaho Falls, Idaho, United States, 83404
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Jeffrey Boyd Baker         
GSK Investigational Site Recruiting
Nampa, Idaho, United States, 83686
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Elaine Davidson         
GSK Investigational Site Recruiting
Nampa, Idaho, United States, 83687
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Gary N Gregerson         
United States, Kansas
GSK Investigational Site Recruiting
El Dorado, Kansas, United States, 67042
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Michael Rausch         
GSK Investigational Site Recruiting
Wichita, Kansas, United States, 67205
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Anna F Stork Fury         
United States, Louisiana
GSK Investigational Site Recruiting
Lafayette, Louisiana, United States, 70508
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Darrell C Robinson         
GSK Investigational Site Recruiting
Slidell, Louisiana, United States, 70458
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Blake C Landry         
United States, Michigan
GSK Investigational Site Recruiting
Flint, Michigan, United States, 48532
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Veena Kalra         
GSK Investigational Site Recruiting
Saginaw, Michigan, United States, 48604
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Andrew Wagner         
United States, Montana
GSK Investigational Site Recruiting
Missoula, Montana, United States, 59804
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Merlin Bardett Fausett         
United States, Nebraska
GSK Investigational Site Recruiting
Norfolk, Nebraska, United States, 68701
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Keith Vrbicky         
United States, New Mexico
GSK Investigational Site Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Quito Osuna Carr         
United States, New York
GSK Investigational Site Recruiting
Johnson City, New York, United States, 13790
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Dhruv Agneshwar         
United States, North Carolina
GSK Investigational Site Recruiting
Hendersonville, North Carolina, United States, 28792
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Kathryn F Patten         
United States, Ohio
GSK Investigational Site Recruiting
Englewood, Ohio, United States, 45322
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Stuart Weprin         
United States, South Carolina
GSK Investigational Site Recruiting
Greenville, South Carolina, United States, 29607
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Scott Robert Dobson         
United States, Texas
GSK Investigational Site Recruiting
Arlington, Texas, United States, 75050
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Dawnette Peppler         
GSK Investigational Site Recruiting
Burleson, Texas, United States, 76028
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Richard R Ondrizek         
GSK Investigational Site Recruiting
Fort Worth, Texas, United States, 76104
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Cynthia Robbins         
GSK Investigational Site Recruiting
Georgetown, Texas, United States, 78626
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: John V Sherman         
GSK Investigational Site Recruiting
Keller, Texas, United States, 76248
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Joseph Richard Kilianski         
GSK Investigational Site Recruiting
League City, Texas, United States, 77573
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Bassem Boutros Maximos         
GSK Investigational Site Recruiting
McAllen, Texas, United States, 78503
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Hearther Asneth Daley         
GSK Investigational Site Recruiting
Mesquite, Texas, United States, 75149
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Salma Saiger         
GSK Investigational Site Recruiting
Plano, Texas, United States, 75093
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: John Paul Roberts         
GSK Investigational Site Recruiting
Weatherford, Texas, United States, 76086
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Stephen Stamatis         
Australia, Queensland
GSK Investigational Site Recruiting
South Brisbane, Queensland, Australia, 4101
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Glenn Gardener         
New Zealand
GSK Investigational Site Recruiting
Auckland, New Zealand, 1010
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Rebecca Griffith         
GSK Investigational Site Recruiting
Newtown, New Zealand, 6021
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Centre    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Principal Investigator: Thorsten Stanley         
Sponsors and Collaborators
GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT04605159    
Other Study ID Numbers: 212171
2020-001355-40 ( EudraCT Number )
First Posted: October 27, 2020    Key Record Dates
Last Update Posted: January 19, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Syncytial Virus Infections
Virus Diseases
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections